These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 2885415)

  • 1. Effects of auranofin and other antirheumatic drugs on human myelopoiesis in vitro.
    Hamilton JA; Williams N
    J Rheumatol; 1987 Apr; 14(2):216-20. PubMed ID: 2885415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro inhibition of myelopoiesis by gold salts and D-penicillamine.
    Hamilton JA; Williams N
    J Rheumatol; 1985 Oct; 12(5):892-6. PubMed ID: 3936930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of slow-acting anti-rheumatic drugs (SAARDs) and combinations of SAARDs on monokine production in vitro.
    Danis VA; Franic GM; Brooks PM
    Drugs Exp Clin Res; 1991; 17(12):549-54. PubMed ID: 1841047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Auranofin, an immunosuppressive drug, inhibits MHC class I and MHC class II pathways of antigen presentation in dendritic cells.
    Han S; Kim K; Song Y; Kim H; Kwon J; Lee YH; Lee CK; Lee SJ; Ha N; Kim K
    Arch Pharm Res; 2008 Mar; 31(3):370-6. PubMed ID: 18409052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulfasalazine has a better efficacy/toxicity profile than auranofin--evidence from a 5 year prospective, randomized trial.
    McEntegart A; Porter D; Capell HA; Thomson EA
    J Rheumatol; 1996 Nov; 23(11):1887-90. PubMed ID: 8923361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antirheumatic agents on the mitogen response of arthritic rat spleen cells.
    Pasternak RD; Marks RL; Hubbs SJ; DiPasquale G
    Res Commun Chem Pathol Pharmacol; 1985 Jun; 48(3):353-67. PubMed ID: 3927458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3.
    Kim NH; Lee MY; Park SJ; Choi JS; Oh MK; Kim IS
    Immunology; 2007 Dec; 122(4):607-14. PubMed ID: 17645497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.
    Broxmeyer HE; Williams DE; Lu L; Cooper S; Anderson SL; Beyer GS; Hoffman R; Rubin BY
    J Immunol; 1986 Jun; 136(12):4487-95. PubMed ID: 3086433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of auranofin and other gold complexes on the activity of phospholipase C.
    Snyder RM; Mirabelli CK; Clark MA; Ziegler JT; Crooke ST
    Mol Pharmacol; 1987 Sep; 32(3):437-42. PubMed ID: 3118179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration of interleukin-1 activity and the acute phase response in adjuvant arthritic rats treated with disease modifying antirheumatic drugs.
    Connolly KM; Stecher VJ; Danis E; Pruden DJ; LaBrie T
    Agents Actions; 1988 Aug; 25(1-2):94-105. PubMed ID: 3142230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Auranofin: first choice for remission-inducing drug (RID) therapy in rheumatoid arthritis?
    Bandilla K; Missler B; Klein-Reesink B
    Scand J Rheumatol Suppl; 1986; 63():47-54. PubMed ID: 3474777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of antirheumatic drugs with the superoxide generation system of activated human polymorphonuclear leukocytes.
    Minta JO; Williams MD
    J Rheumatol; 1986 Jun; 13(3):498-504. PubMed ID: 3016258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination therapy of rheumatoid arthritis].
    Hansen A; Jensen T
    Ugeskr Laeger; 1998 Sep; 160(40):5772-6. PubMed ID: 9782754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia.
    Wisniewski D; Strife A; Atzpodien J; Clarkson BD
    Cancer Res; 1987 Sep; 47(18):4788-94. PubMed ID: 3040231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the effects of pharmacological agents on antigen-induced arthritis in BALB/c mice.
    Crossley MJ; Spowage M; Hunneyball IM
    Drugs Exp Clin Res; 1987; 13(5):273-7. PubMed ID: 2890505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of in vitro and in vivo effects of gold compounds on leukocyte function: possible mechanisms of action.
    Wolach B; DeBoard JE; Coates TD; Baehner RL; Boxer LA
    J Lab Clin Med; 1982 Jul; 100(1):37-44. PubMed ID: 6283001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism.
    Cronstein BN
    Br J Rheumatol; 1995 Nov; 34 Suppl 2():30-2. PubMed ID: 8535646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difference in preventive effects between the phosphodiesterase iv inhibitor rolipram and anti-arthritic drugs on antigen-induced arthritis in mice.
    Yamaki K; Li X; Hossain MA; Alam AH; Taneda S; Yanagisawa R; Takano H; Yoshino S
    Immunol Invest; 2007; 36(2):131-45. PubMed ID: 17365015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line.
    Sugimoto M; Inoue T; Yamashita M; Takeshita K; Nakaike S
    Drugs Exp Clin Res; 2002; 28(5):197-205. PubMed ID: 12635495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current concepts in clinical therapeutics: disease-modifying drugs for rheumatoid arthritis.
    Pugh MC; Pugh CB
    Clin Pharm; 1987 Jun; 6(6):475-91. PubMed ID: 3319362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.